The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 7 of the 58 sources its claims cite were checked for support.
Hippocampal TMEM55B overexpression in the 5XFAD mouse model of Alzheimer's disease
Open accessAbstract
Dysfunction of the endosomal‐lysosomal network is a notable feature of Alzheimer's disease (AD) pathology. Dysfunctional endo‐lysosomal vacuoles accumulate in dystrophic neurites surrounding amyloid β (Aβ) plaques and may be involved in the pathogenesis and progression of Aβ aggregates. Trafficking and thus maturation of these dysfunctional vacuoles is disrupted in the vicinity of Aβ plaques. Transmembrane protein 55B (TMEM55B), also known as phosphatidylinositol‐4,5‐bisphosphate 4‐phosphatase 1 (PIP4P1) is an endo‐lysosomal membrane protein that is necessary for appropriate trafficking of endo‐lysosomes. The present study tested whether overexpression of TMEM55B in the hippocampus could prevent plaque‐associated axonal accumulation of dysfunctional endo‐lysosomes, reduce Aβ plaque load, and prevent hippocampal‐dependent learning and memory deficits in the 5XFAD mouse models of Aβ plaque pathology. Immunohistochemical analyses revealed a modest but significant reduction in the accumulation of endo‐lysosomes in dystrophic neurites surrounding Aβ plaques, but there was no change in hippocampal‐dependent memory or plaque load. Overall, these data indicate a potential role for TMEM55B in reducing endo‐lysosomal dysfunction during AD‐like Aβ pathology.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
Hippocampal overexpression of TMEM55B via AAV9 in 5XFAD mice modestly reduced LAMP1 accumulation in peri-plaque dystrophic neurites but did not alter Aβ plaque load or hippocampal-dependent memory. The authors conclude TMEM55B may have a limited role in reducing endo-lysosomal dysfunction during AD-like Aβ pathology.
Key findings
- AAV9-TMEM55B-GFP treatment in 5XFAD mice significantly reduced LAMP1 intensity within peri-plaque regions (PPRs) compared with saline-treated 5XFAD mice (F(1, 8) = 8.363, p = 0.02), though the effect was modest.
- PPR LAMP1 intensity was nearly two-fold greater than the whole hippocampal section average (F(1, 8) = 263.6, p < 0.0001), and PPR LAMP1-positive area normalized to hippocampal area did not differ between saline- and AAV-TMEM55B-GFP-treated mice (p = 0.9729).
- No treatment effect was found on overall hippocampal LAMP1 intensity, overall hippocampal LAMP1 percent area, or Aβ (D54D2) plaque signal area (p = 0.7542).
- Morris water maze probe trial performance did not differ by genotype or treatment for platform passes (genotype F(1, 16) = 0.05202, p = 0.8225; treatment F(1, 16) = 0.7511, p = 0.3989) or distance to platform (genotype F(1, 16) = 1.101, p = 0.3097; treatment F(1, 16) = 2.936, p = 0.1059); unexpectedly, 5XFAD mice spent more time in the target quadrant than WT mice (F(1, 16) = 8.725, p = 0.0093).
Methods
- 5XFAD mice and WT littermates of both sexes received intrahippocampal stereotaxic injection of AAV9-TMEM55B-GFP or PBS at 2 months of age; behavioral testing occurred at 5 months, 90 days after injection.
- Hippocampal-dependent spatial learning and memory were assessed with the Morris water maze; non-hippocampal memory was assessed with Novel Object Recognition, but NOR data were excluded because several mice failed to meet the minimum 20-second object interaction time.
- Brains were processed for immunohistochemistry against LAMP1, Aβ (D54D2), and GFP, imaged with brightfield fluorescence or confocal microscopy, and analyzed with ImageJ, including a custom method to measure LAMP1 percent area and intensity exclusively within peri-plaque regions.
Limitations
- The paper states that NOR data were excluded because several mice failed to meet the minimum object interaction time of 20 seconds, reducing some groups such that meaningful interpretation was not possible.
- The authors state that 5XFAD is a pathologically aggressive Aβ model and suggest the intervention might be more effective in a model with slower Aβ pathological progression; they also note that 5XFAD and other FAD mice do not display robust age- or pathology-associated cognitive deficits on hippocampal and non-hippocampal memory tasks.
- The authors state that additional studies using different Aβ pathology models, TMEM55B suppression, and more robust TMEM55B overexpression are necessary; they also note that TMEM55B-mediated feedback inhibition of TFEB may underlie the subtle effect observed. Evident from the text: the immunohistochemical and behavioral analyses used small group sizes (N = 4–6 mice), and the study reports only a modest reduction in PPR LAMP1 intensity without changes in plaque load or cognition.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 of 58 cited sources checked · 2 supported · 1 flagged · accuracy not yet measured
- Premisecitation
5XFAD and other FAD mice do not display robust age- or pathology-associated cognitive deficits on hippocampal and non-hippocampal memory tasks.
“Despite the aggressive rate of pathological Aβ aggregation and lysosomal disruption in the 5XFAD and other FAD mice, they do not display robust ageor pathology-associated cognitive deficits on hippocampal and non-hippocampal memory tasks (Jankowsky & Zheng, 2017;Oblak et al., 2021)”
Quote in the paperSubstantial claim2 of 2 sources checked- cites Jankowsky & Zheng, 2017 source
The Cognitive impairment subsection says that nearly all tested APP-overexpression models show spatial learning and memory deficits, and specifically reports cognitive decline in 5XFAD months after amyloid pathology. It cautions that the age and disease stage at which deficits are detected depend on the task, but does not support the categorical claim that these mice lack such deficits. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured - cites Oblak et al., 2021 source
The Results section reports no spatial working-memory deficit in 5XFAD mice at 6 or 12 months on a hippocampal spontaneous-alternation task. The Discussion likewise reports no consistent cognitive impairment in the tested mice, but says cognitive testing was limited in scope. The paper does not establish the claim for other FAD mice or for non-hippocampal memory tasks. (LLM, conf=0.88)
Experimental — accuracy not yet measured
- Premisecitation
TMEM55B expression is dependent on TFEB.
“Interestingly, while TMEM55B expression is dependent on TFEB (Willett et al., 2017), TMEM55B can actually inhibit TFEB nuclear translocation (Hashimoto et al., 2018) thus suppressing expression of lysosomal genes.”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Willett et al., 2017 source
The Results section, “TFEB and TFE3 upregulate TMEM55B in response to starvation,” reports that TFEB increases TMEM55B mRNA and protein and that the starvation-induced increase is TFEB/TFE3-dependent. The claim omits both the starvation condition and TFE3’s role, making TFEB dependence sound more general than the evidence establishes. (LLM, conf=0.85)
Experimental — accuracy not yet measured
- Premisecitation
TMEM55B gene expression does not change throughout the lifespan of 5XFAD mice.
“Notably, TMEM55B gene expression does not change throughout the lifespan of 5XFAD mice, but LAMP1, TFEB, and TFE3 gene expression increases after 12 months of age (Forner et al., 2021).”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Forner et al., 2021 source
The Technical Validation section, “Gene expression changes in 5xFAD mice” (Fig. 8; page unavailable), reports age-related changes in differentially expressed genes but does not identify TMEM55B or establish that its expression remains unchanged. Searches for TMEM55B and for LAMP1, TFEB, and TFE3 expression after 12 months found no passage in our copy establishing the cited sentence’s gene-specific claims. (LLM, conf=0.72)
Experimental — accuracy not yet measured
- Premisecitation
Dysfunction of the endosomal-lysosomal system is directly linked with Aβ deposition.
“Dysfunction of the endosomallysosomal system is also directly linked with Aβ deposition (Lee et al., 2022), oxidative stress (Wendt et al., 2022), and synaptic dysfunction (Adalbert et al., 2009).”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Lee et al., 2022 source
- Findingown data
Overall hippocampal LAMP1 signal intensity did not differ among genotype or treatment groups.
“Although LAMP1 signal intensity was equal among all experimental groups (F (1, 14) = 0.7831, p = 0.3911, main effect of genotype; F (1,14) = 0.3892, p = 0.5428, main effect of treatment; Figure 3B),”
Quote in the paperNot a substantial claim
- Findingown data
LAMP1 fluorescence intensity is strongly enriched within the PPR.
“(F) LAMP1 fluorescence intensity is strongly enriched within the PPR, and PPR LAMP1 intensity is slightly reduced by AAV-55B treatment.”
Quote in the paperNot a substantial claim - Findingown data
Within peri-plaque regions, LAMP1 signal intensity is nearly two-fold greater than the average for the whole hippocampal section.
“Within PPRs, LAMP1 signal intensity was nearly two-fold greater than the average for the whole hippocampal section (2-way ANOVA, F (1, 8) = 263.6,p < 0.0001, main effect of ROI, Figure 3F).”
Quote in the paperSubstantial claim - Findingown data
In 5XFAD mice, AAV-TMEM55B-GFP treatment reduced LAMP1 intensity in regions surrounding Aβ plaques.
“Notably, we observed that LAMP1 intensity in regions surrounding Aβ plaques was reduced (Figure 3F)”
- Also stated in: § Abstract · plain
“PPR LAMP1 intensity is slightly reduced by AAV-55B treatment.”
Quote in the paperSubstantial claim - Also stated in: § Abstract · plain
- Findingown data
In 5XFAD mice, enlarged LAMP1+ vacuoles surrounding Aβ plaques were observed.
“In the present study, enlarged LAMP1+ vacuoles surrounding Aβ plaques were observed”
Quote in the paperSubstantial claim - Findingown data
No significant difference was observed in hippocampal LAMP1 and Aβ immunopositive percent area.
“However, when we assessed hippocampal LAMP1 and Aβ immunopositive percent area (Figure 3C-D), we did not observe a significant difference.”
Quote in the paperSubstantial claim - Findingown data
Saline- and AAV-TMEM55B-GFP-injected mice did not differ in peri-plaque-region LAMP1-positive area normalized as percent of hippocampal area.
“Saline and AAV-TMEM55B-GFP injected mice did not differ in PPR LAMP1 positive area normalized as percent of hippocampal area (p = 0.9729).”
Quote in the paperNot a substantial claim - Findingown data
LAMP1 percent of hippocampal area is reduced in 5XFAD mice compared to WT.
“(C) LAMP1 percent of hippocampal area is reduced in 5XFAD mice compared to WT”
Quote in the paperNot a substantial claim - Findingown data
Wild-type mice displayed significantly greater hippocampal LAMP1-positive area than 5XFAD mice.
“WT mice displayed significantly greater LAMP1 positive area (F (3, 14) = 27.96,main effect of genotype; Figure 3C).”
Quote in the paperNot a substantial claim - Findingown data
Treatment with AAV-TMEM55B-GFP did not affect overall hippocampal LAMP1 area in 5XFAD mice.
“Treatment with AAV-TMEM55B-GFP did not affect overall hippocampal LAMP1 (F (1, 14) = 0.0002968, p = 0.9865, main effect of treatment; Figure 3C) or Aβ (D54D2) plaque signal area (p = 0.7542; Figure 3D).”
Quote in the paperSubstantial claim - Findingown data
Mice learned the location of the hidden platform during the Morris water maze regardless of treatment or genotype (significant main effect of time).
“Mice learned the location of the hidden platform during MWM regardless of treatment or genotype (repeated measures 3-way ANOVA, F (4, 64) = 50.8,p<0.0001, main effect of time, Figure 1A).”
Quote in the paperNot a substantial claim - Findingown data
Mice performed equivalently on the Morris water maze probe trial of spatial memory regardless of genotype or treatment, measured as number of passes over and distance to the platform location.
“Mice performed equivalently on the MWM probe trial of spatial memory regardless of genotype or treatment when measured as number of passes over the platform location (2-way ANOVA, F (1, 16) = 0.05202, p = 0.8225, main effect of genotype; F (1, 16) = 0.7511, p = 0.3989, main effect of treatment; Figure 1B) and distance to platform location (2-way ANOVA F (1, 16) = 1.101, p = 0.3097, main effect of”
Quote in the paperSubstantial claim - Findingown data
No difference in hippocampal LAMP1 intensity with respect to genotype or AAV-55B.
“(B) No difference in hippocampal LAMP1 intensity with respect to genotype or AAV-55B”
Quote in the paperSubstantial claim - Findingown data
No difference in LAMP1 percent of hippocampal area within the PPR.
“(G) No difference in LAMP1 percent of hippocampal area within the PPR.”
Quote in the paperNot a substantial claim - Findingown data
Hippocampal overexpression of TMEM55B in 5XFAD mice modestly but significantly reduces peri-plaque LAMP1 immunopositivity (LAMP1 intensity within peri-plaque regions) relative to saline-treated 5XFAD mice.
“Further, 5XFAD mice treated with AAV-TMEM55B-GFP exhibit modestly but significantly reduced LAMP1 intensity than those treated with saline (F (1, 8) = 8.363, p = 0.02, main effect of treatment, Figure 3F).”
- Also stated in: § Abstract · plain
“In the present study, we find that hippocampal overexpression of TMEM55B modestly reduces peri-plaque LAMP1 immunopositivity.”
- Also stated in: § Abstract · plain
“Immunohistochemical analyses revealed a modest but significant reduction in the accumulation of endo-lysosomes in dystrophic neurites surrounding Aβ plaques, but there was no change in hippocampal-dependent memory or plaque load.”
Quote in the paperSubstantial claim- Rests on an assumption: LAMP1 immunopositivity within peri-plaque regions quantitatively reflects the accumulation of dysfunctional endo-lysosomes in dystrophic neurites.
- Also stated in: § Abstract · plain
- Findingown data
No spatial cognitive/memory deficits were detected in the paper's 5XFAD mice with respect to genotype or treatment.
“Although we were unable to detect any cognitive deficits in our 5XFAD mice”
- Also stated in: § Abstract · plain
“Mice display no spatial cognitive/memory deficits with respect to genotype or treatment.”
Quote in the paperSubstantial claim - Also stated in: § Abstract · plain
- Findingown data
Treatment with AAV-TMEM55B-GFP did not change amyloid β (D54D2) plaque signal area in 5XFAD mice.
“Treatment with AAV-TMEM55B-GFP did not affect overall hippocampal LAMP1 (F (1, 14) = 0.0002968, p = 0.9865, main effect of treatment; Figure 3C) or Aβ (D54D2) plaque signal area (p = 0.7542; Figure 3D).”
Quote in the paperSubstantial claim - Findingown data
5XFAD mice spent significantly more time in the target quadrant than wild-type mice.
“Unexpectedly, 5XFAD mice spent significantly more time in the target quadrant than WT mice (2-way ANOVA, F (1, 16) = 8.725, p = 0.0093, main effect of genotype, Figure 1C).”
Quote in the paperNot a substantial claim - Findingown data
TMEM55B overexpression altered LAMP1 localization in 5XFAD mice.
“Overall, these functions align with the data herein demonstrating that TMEM55B overexpression altered LAMP1 localization in 5XFAD mice.”
Quote in the paperSubstantial claim - Interpretationreasoning
Restoration of retrograde transport of endo-lysosomes may represent a therapeutic strategy to reduce dystrophic neurite pathology as well as amyloid β deposition and neurodegeneration in Alzheimer's disease.
“Therefore, restoration of retrograde transport of endo-lysosomes may represent a therapeutic strategy to reduce not only dystrophic neurite pathology but also Aβ deposition and neurodegeneration during AD.”
Quote in the paperSubstantial claim - Premisecitation
Retrograde transport of autophagic vacuoles is essential for their maturation to functional lysosomes.
“Importantly, retrograde transport of these autophagic vacuoles is essential for their maturation to functional lysosomes (Nixon, 2017).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Nixon, 2017 source
- Premisecitation
The endosomal-lysosomal network is dysfunctional in Alzheimer's disease, evident from the accumulation of autophagic vacuoles in the axons of dystrophic neurites due to disruption of retrograde trafficking, acidification and maturation of endo-lysosomes.
“The endosomal-lysosomal network is dysfunctional in Alzheimer's disease (AD), evident from the accumulation of autophagic vacuoles in the axons of dystrophic neurites due to disruption of retrograde trafficking, acidification, and maturation of endo-lysosomes (Gowrishankar et al., 2015;Lie et al., 2022;Sadleir et al., 2016;Serrano-Pozo et al., 2016).”
Quote in the paperSubstantial claim0 of 3 sources checked - Premisecitation
TMEM55B (PIP4P1) is a key player in the retrograde trafficking of lysosomes in multiple cell types.
“Transmembrane protein 55B (TMEM55B), also known as phosphatidylinositol-4,5bisphosphate 4-phosphatase 1 (PIP4P1), is a key player in the retrograde trafficking of lysosomes in multiple cell types (Araki & Kontani, 2021;Rudnik et al., 2022;Takemasu et al., 2019;Willett et al., 2017).”
Quote in the paperSubstantial claim0 of 3 sources checked - Interpretationcitation
Other pathological processes may be important for cognitive dysfunction in AD.
“suggesting other pathological processes may be important for cognitive dysfunction in AD.”
Quote in the paperSubstantial claim - Premisecitation
5XFAD mice at 2 months of age are at the very earliest stages of amyloid β plaque development.
“at 2 months of age to intervene in adult mice at the very earliest stages of Aβ plaque development (Forner et al., 2015;Oblak et al., 2021).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites Forner et al., 2015
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites Oblak et al., 2021 source
- Premisecitation
Knockout of TMEM55B leads to lysosomal stress and loss of vATPase function related to lysosomal acidification.
“Knockout of TMEM55B leads to lysosomal stress and loss of vATPase function which is related to the acidification of lysosomes (Hashimoto et al., 2018).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Hashimoto et al., 2018 source
- Interpretationown data
The observed enlarged LAMP1+ vacuoles surrounding Aβ plaques demonstrate endosomal-lysosomal network dysfunction in 5XFAD mice.
“demonstrating the endosomal-lysosomal network dysfunction in 5XFAD mice (Figure 3).”
Quote in the paperSubstantial claim - Interpretationown data
TMEM55B expression reduced vacuolar accumulation in neurons surrounding Aβ plaques.
“suggesting that TMEM55B expression reduced vacuolar accumulation in neurons surrounding Aβ plaques.”
Quote in the paperSubstantial claim - Premisecitation
LAMP1, TFEB, and TFE3 gene expression increases after 12 months of age in 5XFAD mice.
“Notably, TMEM55B gene expression does not change throughout the lifespan of 5XFAD mice, but LAMP1, TFEB, and TFE3 gene expression increases after 12 months of age (Forner et al., 2021).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Forner et al., 2021 source
- Interpretationreasoning
Early defects in endo-lysosomal function in 5-month-old 5XFAD mice may not be driven by transcriptional regulation but instead by post-translational processes.
“These data suggest that early defects in endo-lysosomal function in 5-month-old 5XFAD mice herein may not be driven by transcriptional regulation but instead by post-translational processes and thus overexpression of TMEM55B may not be sufficient without altering post-translational processes that regulate TMEM55B function such as phosphorylation (Takemasu et al., 2019).”
Quote in the paperSubstantial claim - Premisecitation
Presenilin function is associated with dysfunctional lysosomal proteolysis and autophagy.
“Presenilin (PS) function, which is disrupted in patients with familial AD mutations in PS, is associated with dysfunctional lysosomal proteolysis and autophagy (Lee et al., 2010;Lie et al., 2022;Neely et al., 2011;Reddy et al., 2016)”
Quote in the paperSubstantial claim0 of 3 sources checked - Interpretationreasoning
The subtle changes observed in LAMP1 intensity surrounding Aβ plaques would be insufficient to modulate cognition in 5XFAD mice.
“it is likely that the subtle changes observed in the intensity of LAMP1 surrounding Aβ plaques would be insufficient to modulate cognition in 5XFAD mice.”
Quote in the paperSubstantial claim - Interpretationown data
Local TMEM55B overexpression had a subtle effect on Aβ plaque-associated LAMP1 pathology in 5XFAD mice.
“Taken together, our results suggest that local TMEM55B overexpression had a subtle effect on Aβ plaque-associated LAMP1 pathology in 5XFAD mice.”
- Also stated in: § Abstract · boosted
“The study herein demonstrates that TMEM55B overexpression has subtle effects on the intensity of LAMP1 surrounding Aβ plaques in 5XFAD mice.”
Quote in the paperSubstantial claim - Also stated in: § Abstract · boosted
- Interpretationown data
The data indicate a potential role for TMEM55B in reducing endo-lysosomal dysfunction during Alzheimer's-disease-like amyloid β pathology.
“Overall, these data indicate a potential role for TMEM55B in reducing endo-lysosomal dysfunction during AD-like Aβ pathology.”
Quote in the paperSubstantial claim- Rests on an assumption: LAMP1 immunopositivity within peri-plaque regions quantitatively reflects the accumulation of dysfunctional endo-lysosomes in dystrophic neurites.
- Rests on an assumption: AAV9-mediated hippocampal expression of TMEM55B-GFP yields functionally active TMEM55B in vivo.
- Premisecitation
Previous deep phenotyping of 5XFAD mice highlights the difficulty of modeling AD-like memory deficits in 5XFAD mice despite recapitulation of other AD-like phenotypes.
“Previous deep phenotyping of 5XFAD mice highlights the difficulty of modeling AD-like memory deficits in 5XFAD mice despite recapitulation of other AD-like phenotypes (Forner et al., 2015;Oblak et al., 2021).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites Forner et al., 2015
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites Oblak et al., 2021 source
- Premisecitation
Dysfunction of the endosomal-lysosomal system is directly linked with synaptic dysfunction.
“Dysfunction of the endosomallysosomal system is also directly linked with Aβ deposition (Lee et al., 2022), oxidative stress (Wendt et al., 2022), and synaptic dysfunction (Adalbert et al., 2009).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Adalbert et al., 2009 source
- Premisecitation
TMEM55B regulates lysosome positioning and trafficking via interaction with the JIP4 motor protein adapter.
“TMEM55B regulates lysosome positioning and trafficking via interaction with the JIP4 motor protein adapter (Willett et al., 2017) independently from its phosphatase function (Takemasu et al., 2019) but dependent on S-palmitoylation (Rudnik et al., 2022).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Willett et al., 2017 source
- Interpretationown data
5XFAD amyloid β pathology induces LAMP1 signal to translocate away from cell bodies and instead accumulate in axonal swellings in peri-plaque regions.
“Taken together, a change in area coverage without a change in intensity and the anatomical distribution within the representative images (Figure 3A and 2C middle panel) illustrate that 5XFAD Aβ pathology induces LAMP1 signal translocate away from cell bodies to instead accumulate in axonal swellings in peri-plaque regions (PPRs).”
Quote in the paperSubstantial claim- Rests on an assumption: LAMP1 immunopositivity within peri-plaque regions quantitatively reflects the accumulation of dysfunctional endo-lysosomes in dystrophic neurites.
- Interpretationreasoning
TMEM55B-mediated feedback inhibition on TFEB translocation may underlie the subtle effect of TMEM55B overexpression on reducing peri-plaque LAMP1+ intensity in dystrophic neurites in 5XFAD mice.
“TMEM55B-mediated feedback inhibition on TFEB translocation may underlie the subtle effect of TMEM55B overexpression on reducing peri-plaque LAMP1+ intensity in dystrophic neurites in 5XFAD mice documented herein.”
Quote in the paperSubstantial claim - Premisecitation
Abnormalities in endosomal-lysosomal processing are an early event that precedes formation of Aβ plaques in numerous mouse models of Aβ pathology.
“However, abnormalities in endosomal-lysosomal processing is an early event that precedes the formation of Aβ plaques in numerous mouse models of Aβ pathology (Lee et al., 2022).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Lee et al., 2022 source
- Premisecitation
Dystrophic neurites are not entirely disrupted.
“However, these dystrophic neurites are not entirely disrupted (Adalbert et al., 2009), suggesting that restoration of trafficking could still result in neuroprotective benefit.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Adalbert et al., 2009 source
- Interpretationreasoning
Restoration of trafficking could still result in neuroprotective benefit.
“suggesting that restoration of trafficking could still result in neuroprotective benefit.”
Quote in the paperSubstantial claim - Interpretationcitation
Overexpression of TMEM55B may not be sufficient without altering post-translational processes that regulate TMEM55B function such as phosphorylation.
“These data suggest that early defects in endo-lysosomal function in 5-month-old 5XFAD mice herein may not be driven by transcriptional regulation but instead by post-translational processes and thus overexpression of TMEM55B may not be sufficient without altering post-translational processes that regulate TMEM55B function such as phosphorylation (Takemasu et al., 2019).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Takemasu et al., 2019 source
- It may state two separate claims as one. 11
- Probably not a substantial claim. 17
It may state two separate claims as one.
PremisecitationLAMP1 is mislocalized to dystrophic neurites in 5XFAD models and in human Alzheimer's disease.
“membrane protein 1 (LAMP1) is mislocalized to dystrophic neurites in 5XFAD models (Forner et al., 2021;Gowrishankar et al., 2015;Wickline et al., 2023) and human AD (Barrachina et al., 2006).”
Quote in the paperSubstantial claim1 of 3 sources checkedIt may state two separate claims as one.
PremisecitationAAV9 has robust tropism for neurons and displays high expression levels in the hippocampus.
“While the promoter was cytomegalovirus (CMV), AAV9 has robust tropism for neurons and displays high expression levels in the hippocampus (Aschauer et al., 2013).”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Aschauer et al., 2013 source
The Results (Efficiency of transgene expression; page unavailable) rank AAV9 highest for expression in the mouse hippocampus. The Discussion (page unavailable) describes strong expression in cortical neurons, but does not establish equally robust neuronal tropism across brain regions; the claim omits that distinction. (LLM, conf=0.83)
Experimental — accuracy not yet measured
It may state two separate claims as one.
Findingown dataSingle intrahippocampal AAV-TMEM55B-GFP injection efficiently labels hippocampus and TMEM55B-GFP colocalizes with endo/lysosomal marker LAMP1.
“Figure 2 . Figure 2. Single intrahippocampal AAV-TMEM55B-GFP injection efficiently labels hippocampus and TMEM55B-GFP colocalizes with endo/lysosomal marker LAMP1.”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Findingown dataFocal GFP expression was found near plaques and in neurons and overlapped with LAMP1 endo-lysosomal staining.
“Focal GFP expression was also found near plaques and in neurons and overlapped with LAMP1 endo-lysosomal staining (Figure 2B & C).”
Quote in the paperNot a substantial claimIt may state two separate claims as one.
Findingown dataIn mice injected with AAV-TMEM55B-GFP there was widespread GFP expression in the hippocampus that extended to other brain areas, which was not present in control mice.
“In mice injected with AAV-TMEM55B-GFP, there was widespread GFP expression in the hippocampus that extended to other brain areas that was not present in control mice (Figure 2A).”
Quote in the paperSubstantial claimProbably not a substantial claim.
PremisecitationNumerous genetic perturbation and pharmacological studies support a protective role of TFEB activation in a variety of neurodegenerative disease models.
“Further, numerous genetic perturbation and pharmacological studies support the protective role of TFEB activation in a variety of neurodegenerative disease models (Gu et al., 2022;Song et al., 2021).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites Gu et al., 2022
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites Song et al., 2021
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
It may state two separate claims as one.
PremisecitationTMEM55B transcription is regulated by the lysosomal regulator TFEB, which is dysregulated in Alzheimer's disease.
“TMEM55B transcription is regulated by the master autophagic and lysosomal regulator TFEB (Willett et al., 2017) which is dysregulated in AD (Zhang & Zhao, 2015).”
Quote in the paperSubstantial claim0 of 2 sources checkedProbably not a substantial claim. The paper’s conclusions may not depend on it.
PremisecitationAccumulation of lysosomes around amyloid β plaques is associated with increased oxidative stress.
“Additionally, accumulation of lysosomes around Aβ plaques is associated with increased oxidative stress (Wendt et al., 2022).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Wendt et al., 2022 source
It may state two separate claims as one.
PremisecitationDisruption of lysosomal trafficking and maturation in Alzheimer's disease pathology leads not only to cellular stress but also to accumulation of extracellular amyloid β.
“When this lysosomal trafficking and maturation process is disrupted in AD pathology (Lie et al., 2022), it not only leads to cellular stress but also the accumulation of extracellular amyloid β (Aβ) (Lee et al., 2022).”
Quote in the paperSubstantial claim0 of 2 sources checkedProbably not a substantial claim. The paper’s conclusions may not depend on it.
PremisecitationTMEM55B regulation of lysosome positioning and trafficking is independent from its phosphatase function.
“TMEM55B regulates lysosome positioning and trafficking via interaction with the JIP4 motor protein adapter (Willett et al., 2017) independently from its phosphatase function (Takemasu et al., 2019) but dependent on S-palmitoylation (Rudnik et al., 2022).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Takemasu et al., 2019 source
Probably not a substantial claim.
PremisecitationThe downstream mechanism of TFEB's protective actions in Alzheimer's disease models most likely involves a restoration of lysosomal homeostasis.
“The downstream mechanism of TFEB's protective actions in AD models are still poorly understood, but most likely involves a restoration of lysosomal homeostasis (Gu et al., 2022;Song et al., 2021).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites Gu et al., 2022
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites Song et al., 2021
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
It may state two separate claims as one.
InterpretationcitationTMEM55B activity may mitigate amyloid β plaque-associated lysosomal dysregulation, perhaps by promoting retrograde trafficking.
“This suggest that TMEM55B activity may mitigate Aβ plaque-associated lysosomal dysregulation perhaps by promoting retrograde trafficking (Willett et al., 2017).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Willett et al., 2017 source
- Rests on an assumption: LAMP1 immunopositivity within peri-plaque regions quantitatively reflects the accumulation of dysfunctional endo-lysosomes in dystrophic neurites.
- Rests on an assumption: AAV9-mediated hippocampal expression of TMEM55B-GFP yields functionally active TMEM55B in vivo.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
PremisecitationTMEM55B localizes to late endosomes and lysosomes.
“TMEM55B localizes to late endosomes and lysosomes and its overexpression mediates lysosomal degradation of internalized epidermal growth factor receptors (Ungewickell et al., 2005).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Ungewickell et al., 2005 source
Probably not a substantial claim. The paper’s conclusions may not depend on it.
PremisecitationTMEM55B regulation of lysosome positioning and trafficking is dependent on S-palmitoylation.
“TMEM55B regulates lysosome positioning and trafficking via interaction with the JIP4 motor protein adapter (Willett et al., 2017) independently from its phosphatase function (Takemasu et al., 2019) but dependent on S-palmitoylation (Rudnik et al., 2022).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Rudnik et al., 2022
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
Study design and conductown dataNovel Object Recognition data were excluded because several mice failed to meet the minimum object interaction time of 20 seconds, reducing some experimental groups such that a meaningful interpretation of the results was not possible.
“However, NOR data was excluded from this publication because several mice failed to meet the minimum object interaction time of 20 seconds which resulted in some experimental groups being reduced such that a meaningful interpretation of the results was not possible.”
Quote in the paperNot a substantial claimIt may state two separate claims as one.
Study design and conductcitationPBS serves as an adequate control for these experiments, because the endo-lysosomal pathway targeted here is not greatly affected by AAV-GFP.
“Our previous work demonstrates that about 400 transcripts, many related to ribosomal processing, are upregulated in AAV-GFP treated hippocampal neurons compared to PBS treated hippocampal neurons (Hopp et al., 2018), suggesting that the endo-lysosomal pathway targeted herein is not greatly affected by AAV-GFP and that PBS can serve as an adequate control for the experiments herein.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Hopp et al., 2018 source
Probably not a substantial claim. The authors may not put it forward as true.
PremisecitationActivating TFEB ameliorates Aβ pathology.
“Others have found that activating TFEB, the master transcriptional regulator of lysosomal biogenesis, ameliorates Aβ pathology (Xiao et al., 2015).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Xiao et al., 2015 source
Probably not a substantial claim. The paper’s conclusions may not depend on it.
PremisecitationAppropriate lysosomal trafficking is vital for maturation and acidification.
“Appropriate lysosomal trafficking is vital for maturation and acidification (Nixon, 2017).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Nixon, 2017 source
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
PremisecitationTMEM55B regulates surface expression of low-density lipoprotein receptor but not transferrin receptor or lipoprotein receptor 1.
“TMEM55B also regulates surface expression of low-density lipoprotein receptor but not transferrin receptor or lipoprotein receptor 1 (Medina et al., 2014;Qin et al., 2020) suggesting its role in receptor trafficking may be cargo specific.”
Quote in the paperNot a substantial claim0 of 2 sources checkedProbably not a substantial claim.
PremisecitationDefects in the endosomal-lysosomal network can impact homeostatic cellular processes including cell signaling, molecular trafficking, and clearance pathways.
“Defects in the endosomal-lysosomal network can impact numerous homeostatic cellular processes including cell signaling, molecular trafficking, and clearance pathways (Nixon, 2017).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Nixon, 2017 source
Probably not a substantial claim. The paper’s conclusions may not depend on it.
PremisecitationTMEM55B overexpression mediates lysosomal degradation of internalized epidermal growth factor receptors.
“TMEM55B localizes to late endosomes and lysosomes and its overexpression mediates lysosomal degradation of internalized epidermal growth factor receptors (Ungewickell et al., 2005).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Ungewickell et al., 2005 source
It may state two separate claims as one.
PremisecitationTMEM55B can inhibit TFEB nuclear translocation, thus suppressing expression of lysosomal genes.
“Interestingly, while TMEM55B expression is dependent on TFEB (Willett et al., 2017), TMEM55B can actually inhibit TFEB nuclear translocation (Hashimoto et al., 2018) thus suppressing expression of lysosomal genes.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Hashimoto et al., 2018 source
Probably not a substantial claim. The paper’s conclusions may not depend on it.
PremisecitationDysfunction of the endosomal-lysosomal system is directly linked with oxidative stress.
“Dysfunction of the endosomallysosomal system is also directly linked with Aβ deposition (Lee et al., 2022), oxidative stress (Wendt et al., 2022), and synaptic dysfunction (Adalbert et al., 2009).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Wendt et al., 2022 source
Probably not a substantial claim.
PremisecitationActivating TFEB ameliorates amyloid β pathology.
“Others have found that activating TFEB ameliorates Aβ pathology (Xiao et al., 2015).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Xiao et al., 2015 source
Probably not a substantial claim. The paper’s conclusions may not depend on it.
InterpretationcitationTMEM55B's role in receptor trafficking may be cargo specific.
“suggesting its role in receptor trafficking may be cargo specific.”
Quote in the paperNot a substantial claimProbably not a substantial claim.
PremisecitationPresenilin function is disrupted in patients with familial AD mutations in PS.
“Presenilin (PS) function, which is disrupted in patients with familial AD mutations in PS, is associated with dysfunctional lysosomal proteolysis and autophagy (Lee et al., 2010;Lie et al., 2022;Neely et al., 2011;Reddy et al., 2016)”
Quote in the paperSubstantial claim0 of 3 sources checkedProbably not a substantial claim. The paper’s conclusions may not depend on it.
PremisecitationTMEM55B is implicated in direct regulation of endo-lysosomal acidification, potentially independently of its trafficking functions.
“TMEM55B is also implicated in direct regulation of endo-lysosomal acidification, potentially independently of its trafficking functions (Hashimoto et al., 2018;Takemasu et al., 2019).”
Quote in the paperNot a substantial claim0 of 2 sources checked
The paper relies on this without support.
LAMP1 immunopositivity within peri-plaque regions quantitatively reflects the accumulation of dysfunctional endo-lysosomes in dystrophic neurites.
“Taken together, a change in area coverage without a change in intensity and the anatomical distribution within the representative images (Figure 3A and 2C middle panel) illustrate that 5XFAD Aβ pathology induces LAMP1 signal translocate away from cell bodies to instead accumulate in axonal swellings in peri-plaque regions (PPRs).”
“Immunohistochemical analyses revealed a modest but significant reduction in the accumulation of endo-lysosomes in dystrophic neurites surrounding Aβ plaques, but there was no change in hippocampal-dependent memory or plaque load.”
The paper relies on this without support.
AAV9-mediated hippocampal expression of TMEM55B-GFP yields functionally active TMEM55B in vivo.
“GFP was fused to the N-terminal of human TMEM55B domain in the plasmid (a kind gift from Jose Martina and Rosa Puertollano) as previously described (Willett et al., 2017).”
The paper relies on this without support.
Few studies have examined the function of TMEM55B.
“Few studies have examined the function of TMEM55B.”
The paper relies on this without support.
The 5XFAD mice used here express mutant PS1 with familial AD mutations.
“the 5XFAD mice used here express mutant PS1 with familial AD mutations.”
The paper relies on this without support.
The 5XFAD mouse model is an aggressive model of Aβ pathology with rapid Aβ-plaque pathology relative to the mouse lifespan.
“The 5XFAD mouse model which overexpression APP and presenilin with a combined 5 familial Alzheimer's disease mutations, is considered a pathologically”
Statistics recomputed
Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.
- ConsistentF(4, 64) = 50.8reported p < .0001 · recomputed p < .001
“F (4, 64) = 50.8,p < .0001”
- ConsistentF(1, 16) = 0.052reported p = .8225 · recomputed p = .822
“F (1, 16) = 0.05202, p = .8225”
- ConsistentF(1, 16) = 0.7511reported p = .3989 · recomputed p = .399
“F (1, 16) = 0.7511, p = .3989”
- ConsistentF(1, 16) = 1.101reported p = .3097 · recomputed p = .310
“F (1, 16) = 1.101, p = .3097”
- ConsistentF(1, 16) = 2.936reported p = .1059 · recomputed p = .106
“F (1, 16) = 2.936, p = .1059”
- ConsistentF(1, 16) = 8.725reported p = .0093 · recomputed p = .009
“F (1, 16) = 8.725, p = .0093”
- ConsistentF(1, 14) = 0.7831reported p = .3911 · recomputed p = .391
“F (1, 14) = 0.7831, p = .3911”
- ConsistentF(1, 14) = 0.3892reported p = .5428 · recomputed p = .543
“F (1,14) = 0.3892, p = .5428”
- ConsistentF(1, 14) = 0.0003reported p = .9865 · recomputed p = .986
“F (1, 14) = 0.0002968, p = .9865”
- ConsistentF(1, 8) = 263.6reported p < .0001 · recomputed p < .001
“F (1, 8) = 263.6,p < .0001”
- ConsistentF(1, 8) = 8.363reported p = .02 · recomputed p = .020
“F (1, 8) = 8.363, p = .02”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Figure 1C caption contradicts the reported genotype effect
MajorThe results report a significant genotype effect on time spent in the target quadrant, but the Figure 1C caption says there was no genotype effect on that measure.
“Unexpectedly, 5XFAD mice spent significantly more time in the target quadrant than WT mice (2-way ANOVA, F (1, 16) = 8.725, p = 0.0093, main effect of genotype, Figure 1C).”
“(C) No genotype or AAV-TMEM55B-GFP (AAV-55B) effects on the probe trial of the MWM by time spent in the target quadrant.”
Citations
Cites
Lee, J.-H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G., et al. (2010) · Cell · doi:10.1016/j.cell.2010.05.008 · Cited by 1,212
Lee, J.-H., Yang, D.-S., Goulbourne, C. N., Im, E., Stavrides, P., Pensalfini, A., Chan, H., Bouchet-Marquis, C., Bleiwas, C., Berg, M. J., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01084-8 · Cited by 638
Aschauer, D. F., Kreuz, S., & Rumpel, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076310 · Cited by 522
Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer’s disease.
Forner, S., Kawauchi, S., Balderrama-Gutierrez, G., Kramár, E. A., Matheos, D. P., Phan, J., Javonillo, D. I., Tran, K. M., Hingco, E., da Cunha, C., et al. (2021) · Scientific Data · doi:10.1038/s41597-021-01054-y · Cited by 501
Practical considerations for choosing a mouse model of Alzheimer’s disease
Jankowsky, J. L., & Zheng, H. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0231-7 · Cited by 449
Gowrishankar, S., Yuan, P., Wu, Y., Schrag, M., Paradise, S., Grutzendler, J., De Camilli, P., & Ferguson, S. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510329112 · Cited by 406
Nixon, R. A. (2017) · The FASEB Journal · doi:10.1096/fj.201700359 · Cited by 400 · cited 4×
“Defects in the endosomal-lysosomal network can impact numerous homeostatic cellular processes including cell signaling, molecular trafficking, and clearance pathways (Nixon, 2017).”
BackgroundInfluentialOblak, A. L., Lin, P. B., Kotredes, K. P., Pandey, R. S., Garceau, D., Williams, H. M., Uyar, A., O’Rourke, R., O’Rourke, S., Ingraham, C., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.713726 · Cited by 325
Sadleir, K. R., Kandalepas, P. C., Buggia-Prévot, V., Nicholson, D. A., Thinakaran, G., & Vassar, R. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1558-9 · Cited by 294
Xiao, Q., Yan, P., Ma, X., Liu, H., Perez, R., Zhu, A., Gonzales, E., Tripoli, D. L., Czerniewski, L., Ballabio, A., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0705-15.2015 · Cited by 238
Willett, R., Martina, J. A., Zewe, J. P., Wills, R., Hammond, G. R. V., & Puertollano, R. (2017) · Nature Communications · doi:10.1038/s41467-017-01871-z · Cited by 201
Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies
Adalbert, R., Nogradi, A., Babetto, E., Janeckova, L., Walker, S. A., Kerschensteiner, M., Misgeld, T., & Coleman, M. P. (2009) · Brain · doi:10.1093/brain/awn312 · Cited by 177
Dysregulation of Nutrient Sensing and CLEARance in Presenilin Deficiency
Reddy, K., Cusack, C. L., Nnah, I. C., Khayati, K., Saqcena, C., Huynh, T., Noggle, S., Ballabio, A., & Dobrowolski, R. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.006 · Cited by 136
Self-citationNeely, K. M., Green, K. N., & LaFerla, F. M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5156-10.2010 · Cited by 134
The identification and characterization of two phosphatidylinositol-4,5-bisphosphate 4-phosphatases
Ungewickell, A., Hugge, C., Kisseleva, M., Chang, S.-C., Zou, J., Feng, Y., Galyov, E. E., Wilson, M., & Majerus, P. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509740102 · Cited by 128
Plaque-associated local toxicity increases over the clinical course of Alzheimer disease
Serrano-Pozo, A., Betensky, R. A., Frosch, M. P., & Hyman, B. T. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.10.010 · Cited by 100
Zhang, Y.-D., & Zhao, J.-J. (2015) · DNA and Cell Biology · doi:10.1089/dna.2014.2738 · Cited by 87
Lysosome‐associated membrane protein 1 (LAMP‐1) in Alzheimer’s disease
Barrachina, M., Maes, T., Buesa, C., & Ferrer, I. (2006) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00756.x · Cited by 83
TFEB in Alzheimer's disease: From molecular mechanisms to therapeutic implications
Gu, Z., Cao, H., Zuo, C., Huang, Y., Miao, J., Song, Y., Yang, Y., Zhu, L., & Wang, F. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105855 · Cited by 66
Lie, P. P. Y., Yoo, L., Goulbourne, C. N., Berg, M. J., Stavrides, P., Huo, C., Lee, J.-H., & Nixon, R. A. (2022) · Science Advances · doi:10.1126/sciadv.abj5716 · Cited by 63
Transcription factor EB: an emerging drug target for neurodegenerative disorders
Song, J., Liu, J., Jiang, Y., Wang, Z., & Li, M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.013 · Cited by 59
TMEM 55B contributes to lysosomal homeostasis and amino acid–induced mTORC 1 activation
Hashimoto, Y., Shirane, M., & Nakayama, K. I. (2018) · Genes to Cells · doi:10.1111/gtc.12583 · Cited by 46
Phosphorylation of TMEM55B by Erk/MAPK regulates lysosomal positioning
Takemasu, S., Nigorikawa, K., Yamada, M., Tsurumi, G., Kofuji, S., Takasuga, S., & Hazeki, K. (2019) · The Journal of Biochemistry · doi:10.1093/jb/mvz026 · Cited by 27
Transmembrane Protein 55B Is a Novel Regulator of Cellular Cholesterol Metabolism
Medina, M. W., Bauzon, F., Naidoo, D., Theusch, E., Stevens, K., Schilde, J., Schubert, C., Mangravite, L. M., Rudel, L. L., Temel, R. E., et al. (2014) · Arteriosclerosis, Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302806 · Cited by 24
Neuronal calcineurin transcriptional targets parallel changes observed in Alzheimer disease brain
Hopp, S. C., Bihlmeyer, N. A., Corradi, J. P., Vanderburg, C., Cacace, A. M., Das, S., Clark, T. W., Betensky, R. A., Hyman, B. T., & Hudry, E. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14469 · Cited by 20
Self-citationWendt, S., Johnson, S., Weilinger, N. L., Groten, C., Sorrentino, S., Frew, J., Yang, L., Choi, H. B., Nygaard, H. B., & MacVicar, B. A. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102448 · Cited by 20
Qin, Y., Ting, F., Kim, M. J., Strelnikov, J., Harmon, J., Gao, F., Dose, A., Teng, B.-B., Alipour, M. A., Yao, Z., et al. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.314033 · Cited by 18
S-palmitoylation determines TMEM55B-dependent positioning of lysosomes
Rudnik, S., Heybrock, S., Säftig, P., & Daμμe, M. (2021) · Journal of Cell Science · doi:10.1242/jcs.258566 · Cited by 11
Regulation of lysosomal positioning via TMEM55B phosphorylation
Araki, M., & Kontani, K. (2021) · The Journal of Biochemistry · doi:10.1093/jb/mvab013 · Cited by 7
Wickline, J. L., Smith, S., Shin, R., Odfalk, K., Sanchez, J., Javors, M., Ginsburg, B., & Hopp, S. C. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109454 · Cited by 2
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Gerasimov, K. A., Ignasheva, Y. E., Dobryakova, Y. V., Korotkova, T., Koryagina, A., Markevich, V. A., & Bolshakov, A. P. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04793-9
BmCPV subverts autophagic flux by suppressing TMEM55B to facilitate viral replication
Mo, X., Song, W., Sui, L., Jiang, S., He, H., Zhang, Y., Cheng, J., Qian, P., & Tang, X. (2026) · Gene · doi:10.1016/j.gene.2026.150417
Metadata
- Authors
- Odfalk, K. F., Wickline, J. L., Smith, S., Dobrowolski, R., & Hopp, S. C.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Rutgers, The State University of New Jersey (US)
- Corresponding author
- Hopp, Sarah C.
- Venue
- Hippocampus
- Publisher
- Wiley
- Published
- 2023-11-14
- Volume
- 34
- Issue
- 1
- Pages
- 29-35
- ISSN
- 1050-9631 (ISSN-L)
- 1098-1063
- PMC
- PMC10873028
- OpenAlex
- W4388659730
- Semantic Scholar
- c1e75a2a63bde5b7aff265372a1825f64ab69678
- Cited by
- 2
- References
- 30
- Citations by year
- 2026: 2
- FWCI
- 0.20
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Hippocampus (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (NS082145, AG066747)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- Alzheimer's disease, 5xFAD mice, amyloid plaques, dystrophic neurites, learning and memory impairment, lysosomal trafficking
- MeSH terms
- Phosphoinositide Phosphatases, Alzheimer Disease, Animals, Disease Models, Animal, Memory Disorders, Mice, Transgenic, Amyloid beta-Peptides, Mice, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review